Why Did the FDA Add a Black Box Warning to Depo-Provera?

The FDA added a black box warning to Depo Provera after clinical trials showed significant bone mineral density loss. This injectable contraceptive, made with medroxyprogesterone acetate, weakens the lumbar spine and femoral neck. This weakness may lead to permanent bone damage, especially in young women who haven’t reached peak bone mass. However, the FDA warning focused only on bone loss and failed to add warnings about brain, breast, or spinal tumors linked to this drug.

If you developed a meningioma, breast, or spinal tumor after using Depo Provera, we can help. Our team at Uptown Injury Law, PLLC, will closely examine your medical records, tumor diagnosis, and Depo Provera use. After this review, we’ll build a solid case and pursue maximum compensation from the drug manufacturer. Call 917-540-8728 now for a free and confidential consultation.

What Are the Reasons for the FDA’s Black Box Warning on Depo-Provera?

The FDA issued a black box warning on Depo Provera due to bone density loss confirmed in clinical studies. In a controlled trial, adult women using Depo Provera CI (150 mg) for up to five years experienced average lumbar spine BMD losses of 2.86% after one year, 4.11% after two years, and 5.38% by year five. Depo Provera users also lost bone density in the femoral neck and total hip over time. In contrast, women in the control group did not experience any significant loss in bone density.

The FDA emphasized that bone loss from Depo Provera may not be completely reversible, especially after long-term use. Studies show that many women do not fully recover their bone density, even after stopping the drug. This is especially concerning for younger women whose bones are still developing. As bone strength weakens over time, the risk of fractures in the spine, hip, and femoral neck increases with age. Because of these risks, the FDA recommends limiting Depo Provera use to two years or less.

How Does the Black Box Warning Impact Depo-Provera Users?

The black box warning has significantly impacted Depo-Provera users by raising awareness of serious risks and encouraging more careful use. It was officially confirmed that prolonged use causes bone mineral density loss, especially in the spine, hip, and neck. Many women only partially recover their bone density, even two years after stopping the drug. Those who used Depo Provera longer showed less recovery during the same timeframe.

After the warning, there have been significant changes in Depo-Provera use, including:

• Doctors must now explain the risks of bone loss and the two-year usage limit before starting treatment.
• Prescribers must consider age, bone health history, and long-term health plans before recommending the drug.
• Patients are more aware; they ask questions, understand long-term effects, and make informed decisions about their birth control options.
• More women are now contacting Depo Provera lawyers after experiencing fractures, bone loss, or tumor diagnoses.

While the FDA added a black box warning for bone loss, it has not added any warning about Depo Provera’s possible link to tumors, despite growing concern. Many women found out about these risks after being diagnosed with serious conditions like meningioma. This lack of transparency has led to legal action against the manufacturer.

What Research and Studies Contributed to the Black Box Warning by the FDA?

In a 48-month study of women aged 18–35, Depo-Provera (DMPA) users lost 7.7% hip BMD and 6.4% spine BMD, mostly within the first two years. After stopping the drug, bone density increased slowly, but long-term users still had lower BMD than baseline, even 18 months later. The study confirms significant bone loss during use and a prolonged recovery period, especially in women about to start menopause.

Supporting this, another study found that women using Depo-Provera (DMPA) for at least five years had significantly lower bone mineral density than premenopausal women. DMPA users had 7.5% less lumbar spine BMD and 6.6% less femoral neck BMD. Their bone density fell between that of premenopausal and postmenopausal women, suggesting that DMPA-induced estrogen suppression negatively affects bone health.

Moreover, a PubMed-indexed study comparing 72 women using Depo-Provera (DMPA) for at least one year to 64 nonusers found significantly lower bone density. DMPA users had much lower estradiol levels (55.7 pg/mL vs. 149.9 pg), confirming that the drug suppresses estrogen (one of the main causes of bone density loss). Together, these findings provided clear scientific evidence that DMPA use leads to bone loss, forcing the FDA to issue a black box warning.

How Have Depo-Provera Lawsuits Evolved Since the FDA Warning Was Issued?

Depo-Provera lawsuits now focus on serious health risks like meningioma and tumors in the brain and spine. You may have seen earlier lawsuits centered around bone mineral density loss and fracture injuries. However, recent cases highlight the drug’s possible connection to hormone-sensitive tumors like breast cancer and meningioma.

These lawsuits argue that Pfizer failed to inform women about the risks associated with the long-term use of medroxyprogesterone acetate. Some claims highlight that doctors disproportionately prescribed the drug to Black and underserved women, raising concerns about systemic negligence. As awareness grows, more women are coming forward with legal claims involving long-term damage and delayed diagnosis.

If you’ve developed meningioma, breast cancer, or another hormone-sensitive tumor after using Depo-Provera, you’re not alone. Our team is actively investigating Pfizer for failing to warn women about these risks. Contact us today for a free case review.

What Are the FDA’s Guidelines for Using Depo-Provera?

The FDA recommends that Depo-Provera (medroxyprogesterone acetate) be used only as a long-term birth control method if no other options are suitable. Due to the increased risk of bone mineral density loss, the agency advises limiting use to two years. This guideline applies especially to young women whose bones are still developing and who may face irreversible damage.

Doctors must clearly explain the black box warning to every patient before starting Depo-Provera. They should review each patient’s medical history, bone health, and overall risk factors. Moreover, the drug label warns about using Depo-Provera CI only for intramuscular use every three months. Beyond this, the FDA outlines several additional precautions for safe use:

• Do not use it if you have a history of blood clots, stroke, or other thromboembolic disorders.
• Confirm a negative pregnancy test before giving each injection.
• Use with caution when prescribing to patients with liver disease, as the liver processes the drug.
• Check blood pressure and liver function regularly during long-term use.
• Track weight since prolonged use often leads to weight gain.
• Monitor blood sugar levels closely in patients with diabetes, as the drug can reduce glucose tolerance.
• It may cause mood changes or worsen depression in sensitive individuals.

Is Depo-Provera Currently Under FDA Recall?

No, Depo-Provera is not currently under recall, and the FDA has not taken action against it. Many women have reported serious side effects, including bone density loss and hormone-related tumors, after extended Depo-Provera use. Doctors still prescribe the drug as a contraceptive, even as safety concerns grow among patients and researchers. The FDA monitors its safety but has not taken action to remove the drug or restrict access to the market.

If Depo Provera Has Affected Your Health, Contact Uptown Injury Law, PLLC — We Will Build A Strong Case for You!

Developing brain tumors or bone loss after Depo-Provera use can leave you in pain and stress. You may be dealing with medical treatments, high medical expenses, and lost income. Other than that, long-term DMPA use, estrogen suppression, and hidden risks only make things more complicated. These challenges affect your body, finances, and peace of mind, especially when you were never warned about the dangers linked to this contraceptive.

Uptown Injury Law, PLLC, helps you pursue justice and financial recovery through a product liability claim. Our attorneys review your Depo-Provera use, tumor or bone loss diagnosis, and essential medical records to build a strong case. We hold the drugmaker companies accountable for failing to warn you about serious risks. Whether through settlement or trial, we fight for the compensation you deserve. Call 917-540-8728 now to consult our team and get the legal support you deserve. You can also visit our law firm at 2417 Third Ave, Suite 505, Bronx, NY 10451.

FAQs